Vicore Partners with Citi to Expand Respiratory Drug Access to American Investors, Citi Named Depositary Bank For Vicore Pharma’s US Shares

Citigroup Inc.

Citigroup Inc.

C

0.00

Citi Issuer Services, acting through Citibank N.A., has been appointed by Vicore Pharma Holding AB ("Vicore Pharma"), a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), to act as Depositary Bank for its sponsored Level 2 American Depositary Receipt ("ADR") program.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.